GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Mesoblast Ltd (NAS:MESO) » Definitions » Total Equity

MESO (Mesoblast) Total Equity : $461.26 Mil (As of Dec. 2024)


View and export this data going back to 2010. Start your Free Trial

What is Mesoblast Total Equity?

Mesoblast's total equity for the quarter that ended in Dec. 2024 was $461.26 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

Mesoblast Total Equity Historical Data

The historical data trend for Mesoblast's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mesoblast Total Equity Chart

Mesoblast Annual Data
Trend Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24
Total Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 549.33 581.40 497.04 501.84 480.36

Mesoblast Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Total Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 508.73 - 480.36 - 461.26

Mesoblast Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

Mesoblast's Total Equity for the fiscal year that ended in Jun. 2024 is calculated as

Total Equity=Total Assets(Q: Jun. 2024 )-Total Liabilities(Q: Jun. 2024 )
=669.153-188.798
=480.36

Mesoblast's Total Equity for the quarter that ended in Dec. 2024 is calculated as

Total Equity=Total Assets(Q: Dec. 2024 )-Total Liabilities(Q: Dec. 2024 )
=653.318-192.056
=461.26

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Mesoblast Total Equity Related Terms

Thank you for viewing the detailed overview of Mesoblast's Total Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Mesoblast Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Mesoblast Ltd (NAS:MESO) » Definitions » Total Equity
Comparable Companies
ASX:NEU ASX:OPT ASX:CU6 ASX:BOT ASX:PYC ASX:CUV ASX:IMM ASX:OCC ASX:IMU ASX:DXB VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX XBRU:UCB ALNY ONC BNTX XKRX:068270
Traded in Other Exchanges
MEOBF:USA LWB:Germany LWB1:Germany MSB:Australia
Address
55 Collins Street, Level 38, Melbourne, VIC, AUS, 3000
Website
https://www.mesoblast.com
Mesoblast Ltd is a biotechnology company. It uses its proprietary technology platform to develop and commercialize allogeneic cellular medicines to treat complex diseases resistant to conventional standards of care and where inflammation plays a central role. The company's product candidates include; Ryoncil (remestemcel-L) for the treatment of steroid refractory acute graft versus host disease as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of cell technology platform for commercialization.